Citations

Clear

4610 citation(s) found for "Lu, Brian".

Entrapment of a Pacing Lead within a Chiari Network: Utility of Intracardiac Echo and a Laser Sheath
Aung, Htin , Espinosa, Raúl E. , Powell, Brian D. , McLeod, Christopher J.

Mayo Clinic

Pacing and Clinical Electrophysiology | February 13, 2016 | Volume: 39 | Issue: 6 | Pages: 620-622

10.1111/pace.12828 | PMID 26873294 Get It

Primary Pseudomyogenic Hemangioendothelioma of Bone
Inyang, Alero F., Mertens, Fredrik , Puls, Florian , Vaiyapuri, Sumathi , Inwards, Carrie Y., Folpe, Andrew L. , Zhang, Yaxia , Symmans, Pennie, Nielsen, G. Petur , Nguyễn, Văn Hùng , Rosenberg, Andrew E. , Inyang, Alero, Lee, Cheng‐Han , Rubin, Brian P.

Mayo Clinic

American Journal of Surgical Pathology | February 12, 2016 | Volume: 40 | Issue: 5 | Pages: 587-598

10.1097/pas.0000000000000613 | PMID 26872012 Get It

Pseudomyogenic hemangioendothelioma (PMH) is a well-recognized neoplasm that usually arises in the soft tissue; concurrent bone involvement occurs in 24% of cases. PMH of bone without soft tissue involvement is rare. We describe the clinicopathologic findings of 10 such cases, the largest series reported to date. The study included 9 male and 1 female patient; their ages ranged from 12 to 74 years (mean 36.7 y). All patients had multiple tumors with a distinct regional distribution: 45% restricted to the lower extremity; 25% to the spine and pelvis; and 15% to the upper extremity. On imaging studies the tumors were well circumscribed and lytic. The neoplasms were composed of spindled cells arranged in intersecting fascicles with scattered epithelioid cells; epithelioid cells predominated in 3 cases. The neoplastic cells contained abundant densely eosinophilic cytoplasm and vesicular nuclei. There was limited cytologic atypia and necrosis, few mitoses (0 to 2/10 high-power fields), and inconspicuous stroma. Unique findings included abundant intratumoral reactive woven bone and hemorrhage with numerous osteoclast-like giant cells. Immunohistochemically, most tumors were positive for keratin, ERG, and CD31; CD34 was negative. The balanced t(7:19)(q22;13) translocation was documented in 3 cases. Follow-up is limited, but no patient developed documented visceral dissemination, and all have stable or progressive osseous disease. PMH exclusively involving bone is rare. It is multicentric, often involves the lower extremity, and has unusual morphology. The differential diagnosis includes epithelioid vascular neoplasms, giant cell tumor, bone forming neoplasms, and metastatic carcinoma. Because of its rarity, unusual presentation, and morphology, accurate diagnosis can be challenging.
Humoral and Cell-Mediated Immune Responses to Alternate Booster Schedules of Anthrax Vaccine Adsorbed in Humans
Quinn, Conrad P. , Sabourin, Carol L., Schiffer, Jarad , Semenova, Vera , Rudge, Thomas L. , Brys, April M., Mittler, Robert S., Ibegbu, Chris, Wrammert, Jens , Ahmed, Rafi , Parker, Scott , Babcock, Janiine , Keitel, Wendy A., Keyserling, Harry, Marano, Nina, Plikaytis, Brian D., Wright, Jennifer G. , Jacobson, Robert M. , Niemuth, Nancy A. , Li, Han , Poland, Gregory A. , Sahly, Hana M. El , Ahmed, Rafi

Mayo Clinic

Clinical and Vaccine Immunology | February 11, 2016 | Volume: 23 | Issue: 4 | Pages: 326-338

10.1128/cvi.00696-15 | PMID 26865594 Get It

ABSTRACT Protective antigen (PA)-specific antibody and cell-mediated immune (CMI) responses to annual and alternate booster schedules of anthrax vaccine adsorbed (AVA; BioThrax) were characterized in humans over 43 months. Study participants received 1 of 6 vaccination schedules: a 3-dose intramuscular (IM) priming series (0, 1, and 6 months) with a single booster at 42 months (4-IM); 3-dose IM priming with boosters at 18 and 42 months (5-IM); 3-dose IM priming with boosters at 12, 18, 30, and 42 months (7-IM); the 1970 licensed priming series of 6 doses (0, 0.5, 1, 6, 12, and 18 months) and two annual boosters (30 and 42 months) administered either subcutaneously (SQ) (8-SQ) or IM (8-IM); or saline placebo control at all eight time points. Antibody response profiles included serum anti-PA IgG levels, subclass distributions, avidity, and lethal toxin neutralization activity (TNA). CMI profiles included frequencies of gamma interferon (IFN-γ)- and interleukin 4 (IL-4)-secreting cells and memory B cells (MBCs), lymphocyte stimulation indices (SI), and induction of IFN-γ, IL-2, IL-4, IL-6, IL-1β, and tumor necrosis factor alpha (TNF-α) mRNA. All active schedules elicited high-avidity PA-specific IgG, TNA, MBCs, and T cell responses with a mixed Th1-Th2 profile and Th2 dominance. Anti-PA IgG and TNA were highly correlated (e.g., month 7, r 2 = 0.86, P < 0.0001, log 10 transformed) and declined in the absence of boosters. Boosters administered IM generated the highest antibody responses. Increasing time intervals between boosters generated antibody responses that were faster than and superior to those obtained with the final month 42 vaccination. CMI responses to the 3-dose IM priming remained elevated up to 43 months. (This study has been registered at ClinicalTrials.gov under registration no. NCT00119067.)
Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
Choueiri, Toni K. , Fay, André P. , Velasco, Guillermo de , Tyburczy, Magdalena E. , Hamieh, Lana , Albigès, Laurence , Ho, Thai H. , Song, Jiaxi , Pignon, Jean‐Christophe , Barrios, Pablo M. , Michaelson, M. Dror , Krajewski, Katherine M. , Porta, Camillo , Pal, Sumanta K. , Heng, Daniel Y.C., Gray, Kathryn P. , Kwiatkowski, David J. , Rini, Brian I. , Thorner, Aaron R. , Agarwal, Neeraj , Van Allen, Eliezer M , Bellmunt, Joaquim , McDermott, David F. , Signoretti, Sabina , Ho, Thai , Choueiri, Toni K

Mayo Clinic

Clinical Cancer Research | February 1, 2016 | Volume: 22 | Issue: 10 | Pages: 2445-2452

10.1158/1078-0432.ccr-15-2631 | PMID 26831717 Get It

Abstract Purpose: We examined the hypothesis that mutations in mTOR pathway genes are associated with response to rapalogs in metastatic renal cell carcinoma (mRCC). Experimental Design: We studied a cohort of mRCC patients who were treated with mTOR inhibitors with distinct clinical outcomes. Tumor DNA from 79 subjects was successfully analyzed for mutations using targeted next-generation sequencing of 560 cancer genes. Responders were defined as those with partial response (PR) by RECIST v1.0 or stable disease with any tumor shrinkage for 6 months or longer. Nonresponders were defined as those with disease progression during the first 3 months of therapy. Fisher exact test assessed the association between mutation status in mTOR pathway genes and treatment response. Results: Mutations in MTOR, TSC1, or TSC2 were more common in responders, 12 (28%) of 43, than nonresponders, 4 (11%) of 36 (P = 0.06). Mutations in TSC1 or TSC2 alone were also more common in responders, 9 (21%), than nonresponders, 2(6%), (P = 0.05). Furthermore, 5 (42%) of 12 subjects with PR had mutations in MTOR, TSC1, or TSC2 compared with 4 (11%) of 36 nonresponders (P = 0.03). Eight additional non-mTOR pathway genes were found to be mutated in at least 4 of 79 tumors (5%); none were associated positively with response. Conclusions: In this cohort of mRCC patients, mutations in MTOR, TSC1, or TSC2 were more common in patients who experienced clinical benefit from rapalogs than in those who progressed. However, a substantial fraction of responders (24 of 43, 56%) had no mTOR pathway mutation identified. Clin Cancer Res; 22(10); 2445–52. ©2016 AACR. See related commentary by Voss and Hsieh, p. 2320
Radiographic size of retroperitoneal lymph nodes predicts pathological nodal involvement for patients with renal cell carcinoma: development of a risk prediction model
Gershman, Boris , Takahashi, Naoki , Moreira, Daniel M. , Thompson, R. Houston, Boorjian, Stephen A. , Lohse, Christine M. , Costello, Brian A. , Cheville, John C. , Leibovich, Bradley C. , Thompson, Robert H, Takahashi, Naoki

Mayo Clinic

BJU International | January 22, 2016 | Volume: 118 | Issue: 5 | Pages: 742-749

10.1111/bju.13424 | PMID 26800148 Get It

Objectives To evaluate the ability of clinical and radiographic features to predict lymph node (pN1) disease among patients with renal cell carcinoma undergoing radical nephrectomy (RN), and to develop a preoperative risk prediction model. Patients and Methods In all, 220 patients with preoperative computed tomography scans available for review underwent RN with lymph node dissection (LND) from 2000 to 2010. Radiographic features were assessed by one genitourinary radiologist blinded to pN status. Associations of features with pN1 disease were evaluated using logistic regression to develop predictive models. Model performance was assessed using area under the receiver operating characteristic curve (AUC) and decision curve analysis. Results The median (interquartile range) lymph node yield was 10 (5–18). In all, 55 patients (25%) had pN1 disease at RN. On univariable analysis, the maximum lymph node (LN) short axis diameter [odds ratio (OR) 1.17; P < 0.001] predicted pN1 disease with an AUC of 0.84. Although several clinical and radiographic features were associated with pN1 disease, only two were retained in the multivariable model: maximum LN short axis diameter (OR 1.19; P <0.001) and radiographic perinephric/sinus fat invasion (OR 44.64; P = 0.01), with an AUC of 0.85. On decision curve analysis, the single variable and multivariable models showed similar net benefit. Conclusion Two radiographic features, maximum LN short axis diameter and perinephric/sinus fat invasion, outperformed traditional clinical variables in predicting pN1 disease. Maximum LN short axis diameter alone showed excellent predictive performance, and, if validated externally, would provide for a simple model to guide patient selection for LND.
AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth
Hu, Brian , Fairey, Adrian, Madhav, Anisha, Yang, Dongyun , Li, Meng , Groshen, Susan , Stephens, Craig, Kim, Philip H., Virk, Navneet, Martin, Sue Ellen , Erho, Nicholas , Jenkins, Robert B., Den, Robert B. , Xu, Tong , Xu, Yucheng, Gill, Inderbir S. , Goldkorn, Amir , Wang, Lina , Davicioni, Elai , Quinn, David I , Den, Robert B , Gill, Inderbir S

Mayo Clinic

The Prostate | January 16, 2016 | Volume: 76 | Issue: 6 | Pages: 597-608

10.1002/pros.23151 | PMID 26771938 Get It

Concordant and Discordant Cardiac Magnetic Resonance Imaging Delayed Hyperenhancement Patterns in Patients with Ischemic and Non-Ischemic Cardiomyopathy
Kim, Eun Kyoung , Chang, Sung‐A , Choi, Jin‐Oh , Glockner, James F., Shapiro, Brian P. , Jang, Shin Yi , Kim, Sung Mok , Oh, Jae K. , Glockner, James, Fine, Nowell, Miller, Wayne, Choe, Yeon Hyeon , Fine, Nowell Mark , Miller, Wayne L. , Lee, Sang‐Chol

Mayo Clinic

Korean Circulation Journal | January 15, 2016 | Volume: 46 | Issue: 1 | Pages: 41

10.4070/kcj.2016.46.1.41 | PMID 26798384 Get It

Validation of a bone scan positivity risk table in non‐metastatic castration‐resistant prostate cancer
Freedland, Stephen J. , Howard, Lauren E. , Hanyok, Brian T. , Kadiyala, Vishnu , Kuang, Jameson, Whitney, Colette , Wilks, Floyd , Amling, Christopher L. , Moreira, Daniel M. , Kane, Christopher J. , Terris, Martha K. , Cooperberg, Matthew R , Aronson, William J. , Howard, Lauren E

Mayo Clinic

BJU International | January 13, 2016 | Volume: 118 | Issue: 4 | Pages: 570-577

10.1111/bju.13405 | PMID 26762961 Get It

Objectives To test the external validity of a previously developed risk table, designed to predict the probability of a positive bone scan among men with non‐metastatic (M0) castration‐resistant prostate cancer ( CRPC ), in a separate cohort. Patients and Methods We retrospectively analysed 429 bone scans of 281 patients with CRPC , with no known previous metastases, treated at three Veterans Affairs Medical Centers. We assessed the predictors of a positive scan using generalized estimating equations. Area under the curve ( AUC ), calibration plots and decision‐curve analysis were used to assess the performance of our previous model to predict a positive scan in the current data. Results A total of 113 scans (26%) were positive. On multivariable analysis, the only significant predictors of a positive scan were log‐transformed prostate‐specific antigen ( PSA ): hazard ratio ( HR ) 2.13; 95% confidence interval ( CI ) 1.71–2.66 ( P < 0.001) and log‐transformed PSA doubling time ( PSADT ): HR 0.53; 95% CI 0.41–0.68 ( P < 0.001). Among men with a PSA level <5 ng/ mL , the rate of positive scans was 5%. The previously developed risk table had an AUC of 0.735 to predict positive bone scan with excellent calibration, and provided additional net benefit in the decision‐curve analysis. Conclusion We have validated our previously developed table to predict the risk of a positive bone scan among men with M0/Mx CRPC . Use of this risk table may allow better tailoring of patients' scanning to identify metastases early, while minimizing over‐imaging. Regardless of PSADT , positive bone scans were rare in men with a PSA <5 ng/ mL .
A Multimodal Imaging Protocol, 123I/99Tc‐Sestamibi, SPECT, and SPECT/CT, in Primary Hyperparathyroidism Adds Limited Benefit for Preoperative Localization
Lee, Grace S. , McKenzie, Travis J. , Mullan, Brian P., Farley, David R. , Thompson, Geoffrey B. , Richards, Melanie L.

Mayo Clinic

World Journal of Surgery | January 5, 2016 | Volume: 40 | Issue: 3 | Pages: 589-594

10.1007/s00268-015-3389-6 | PMID 26732668 Get It

AbstractIntroductionFocused parathyroidectomy in primary hyperparathyroidism (1°HPT) is possible with accurate preoperative localization and intraoperative PTH monitoring (IOPTH). The added benefit of multimodal imaging techniques for operative success is unknown.MethodPatients with 1°HPT, who underwent parathyroidectomy in 2012–2014 at a single institution, were retrospectively reviewed. Only the patients who underwent the standardized multimodal imaging workup consisting of 123I/99Tc‐sestamibi subtraction scintigraphy, SPECT, and SPECT/CT were assessed.ResultsOf 360 patients who were identified, a curative operation was performed in 96 %, using pre‐operative imaging and IOPTH. Imaging analysis showed that 123I/99Tc‐sestamibi had a sensitivity of 86 % (95 % CI 82–90 %), positive predictive value (PPV) 93 %, and accuracy 81 %, based on correct lateralization. SPECT had a sensitivity of 77 % (95 % CI 72–82 %), PPV 92 % and accuracy 72 %. SPECT/CT had a sensitivity of 75 % (95 % CI 70–80 %), PPV of 94 %, and accuracy 71 %. There were 3 of 45 (7 %) patients with negative sestamibi imaging that had an accurate SPECT and SPECT/CT. Of 312 patients (87 %) with positive uptake on sestamibi (93 % true positive, 7 % false positive), concordant findings were present in 86 % SPECT and 84 % SPECT/CT. In cases where imaging modalities were discordant, but at least one method was true‐positive, 123I/99Tc‐sestamibi was significantly better than both SPECT and SPECT/CT (p < 0.001). The inclusion of SPECT and SPECT/CT in 1°HPT imaging protocol increases patient cost up to 2.4‐fold.Conclusion123I/99Tc‐sestamibi subtraction imaging is highly sensitive for preoperative localization in 1°HPT. SPECT and SPECT/CT are commonly concordant with 123I/99Tc‐sestamibi and rarely increase the sensitivity. Routine inclusion of multimodality imaging technique adds minimal clinical benefit but increases cost to patient in high‐volume setting.
Outcomes following watchful waiting for stage II–IV follicular lymphoma patients in the modern era
Sinha, Rajni, Byrtek, Michelle, Ziemiecki, Ryan , Zhou, Xiaolei , Friedberg, Jonathan W. , Link, Brian K. , Dawson, Keith, Flowers, Christopher R. , Nastoupil, Loretta J. , Taylor, Michael, Cerhan, James R. , Link, Brian K

Mayo Clinic

British Journal of Haematology | January 5, 2016 | Volume: 172 | Issue: 5 | Pages: 724-734

10.1111/bjh.13895 | PMID 26729445 Get It

SummaryTo examine the effectiveness of an initial management strategy of watchful waiting for follicular lymphoma (FL) in clinical practice, we compared outcomes for patients diagnosed 2004–2007 in the United States initially managed with watchful waiting with outcomes following initial rituximab monotherapy and chemoimmunotherapy. In total, 1754 stage II–IV patients in the National LymphoCare Study underwent watchful waiting (n = 386), rituximab monotherapy (n = 296) or rituximab plus chemotherapy (n = 1072) as initial management strategy. Female patients and those who received treatment in the Northeast or in an academic setting more commonly underwent watchful waiting versus initial chemoimmunotherapy; whereas patients with grade 3 histology, anaemia, elevated lactate dehydrogenase, extranodal involvement, B symptoms or performance status ≥1 more commonly received chemoimmunotherapy. Although time to new treatment and progression‐free survival following first‐ and second‐line therapy were improved with chemoimmunotherapy, and time to chemotherapy was improved with rituximab monotherapy, there were no differences in overall survival between watchful waiting and chemoimmunotherapy or rituximab monotherapy. With 8‐year overall survival estimates of 74%, initial management with watchful waiting in the context of sequential therapy remains a viable option for FL patients in the modern era. This trial was registered at www.clinicaltrials.gov (NCT00097565).